WINSTON-SALEM, N.C., Feb. 3 /PRNewswire-USNewswire/ -- The Regenerative Medicine Foundation today announcedthe first annual Translational Regenerative Medicine Forum to be held April 6-8, 2010 at the Benton Convention Center in Winston-Salem.
The forum seeks to advance the field of regenerative
"The Translational Regenerative Medicine Forum is designed to be the premiere international event for leaders in regenerative medicine translation, representing academic and clinical research, health care policy, venture investment and biotechnology industry interests," said Anthony Atala, M.D., director, Wake Forest Institute for Regenerative Medicine, and a forum speaker. "The body's natural capacity for healing has been known for generations, and the field of regenerative medicine exists to harness this natural healing process. It takes a collaborative approach to address the challenges of delivering regenerative medicine therapies to patients in a timely and cost-effective manner, and it is our expectation that this forum will bring together all the elements and fulfill the promise of the research."
Keynote speakers and plenary panelists include Steven Bauer, Ph.D., chief of the Cell and Tissue Therapy Branch, FDA Center for Biologics Evaluation and Research; Richard Caruso, Ph.D., founder and chairman of the board, Integra; Juan Enriquez, managing director, Excel Venture Management; Robert Klein, chairman, California Institute for Regenerative Medicine; Robert Lanza, M.D., chief scientific officer, Advanced Cell Technology; Lesa Mitchell, vice president, Kauffman Foundation; Sherrill Neff, founding partner, Quaker BioVentures; and Teruo Okano, Ph.D., professor and director of the Institute of Advanced Biomedical Engineering and Science, Tokyo Women's Medical University.
Also, Buddy Ratner, Ph.D., professor of bioengineering and chemical engineering, University of Washington; and Camillo Ricordi, M.D., Diabetes Research Institute, University of Miami Miller School of Medicine; Lt. Gen. Eric Schoomaker, M.D., Ph.D., surgeon general/commander, U.S. Army Medical Command; Andrew von Eschenbach, M.D., former U.S. Food and Drug Administration Commissioner who is now senior advisor with Greenleaf Health and the Center for Health Transformation; John Walker, CEO, iPierian; and Jay Watkins, managing director, DeNovo Ventures.
Translational Forum attendees will include executives from biotechnology, pharmaceutical and medical device, and regenerative medicine companies; patient advocacy groups and medical research foundations; institutional investors from private equity and venture capital firms; academic researchers, clinical researchers and physicians; and those interested in health care innovation and personalized medicine.
To foster interaction between investors and entrepreneurs, the forum will showcase 15 regenerative medicine companies presenting in front of an audience of venture capitalists and corporate venture executives.
For more information and to register, go to www.rmconferences.org
About the Regenerative Medicine Foundation
The Regenerative Medicine Foundation (www.regenerativemedicinefoundation.org) is an internationally focused, not-for-profit organization created to enable the advancement of new treatments and therapies based on regenerative medicine, and ultimately, to realize the goals of personalized medicine.
Launched in 2005, the Foundation hosted one of the first regulatory meetings with the U.S. Food and Drug Administration (FDA) on the topic of regenerative medicine, and was instrumental in the formation of STRAC, the Soldier Treatment and Regeneration Consortium, a precursor to the Armed Forces Institute of Regenerative Medicine (AFIRM), and the Washington, DC-based Alliance for Regenerative Medicine.
Through educational programs, translational conferences and public policy initiatives, the Foundation advocates for increased medical research, promotes the training and education of scientists, and facilitates the translation of therapies to patients.
SOURCE Regenerative Medicine Foundation
Subscribe to our Free Newsletters!
Aniridia is a genetic eye disorder in which the iris is partially or entirely absent. It is ...